October 4, 2018
RESTON, Va. – The Society of Nuclear Medicine and Molecular Imaging commend Congressmen George Holding (NC-2) and Seth Moulton (MA-6) for introducing legislation that recognizes diagnostic radiopharmaceuticals as drugs in the Medicare Hospital Outpatient Prospective Payment System.
“Nuclear medicine and molecular imaging rely on radiopharmaceuticals to both diagnose and treat disease,” said Satoshi Minoshima, MD, PhD. “These procedures are on the cutting edge—providing safe, painless and cost-effective ways for physicians to gather medical information that would otherwise be unavailable. H.R. 6948 will help make this a reality for more patients.”
The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 ensures equitable payment and patient access to diagnostic radiopharmaceuticals, which are used in nuclear medicine procedures.
Nuclear medicine imaging procedures are noninvasive, safe and painless and are used in the diagnosis and evaluation of treatment of multiple diseases and disorders, improving the accuracy with which physicians can diagnose and determine the severity of disease. As a result, patients can avoid unnecessary tests and procedures, and physicians can develop better treatment strategies for cancers and diseases such as prostate, breast, colon and lung.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.